Biomarin Pharmaceutical Inc (BMRN)
BioMarin Pharmaceutical develops and sells medicines for people with rare genetic diseases. It last closed at $58.51 on Nov 17, up 0.90% on the day. BMRN last reported earnings on Mon, Nov 2, 2026. The average 12-month price target from 9 analysts is $89.56 (+53.1% from the last close), with a high of $114.00 and a low of $60.00. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (7 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in BMRN, 50% of them bullish and 50% bearish. In the past 30 days there were 2 dark pool prints totaling $2.7M, the largest $1.7M.
Key Stats
Last 12 monthsNot reported for this period.
From BMRN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 9 analysts who set a price target on BMRN in the past 90 days. The average target is $89.56, with a high of $114.00 and a low of $60.00, compared with the last close of $58.51.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Morgan Stanley | Target lowered | Buy | $122 → $103 |
| Nov 4 | JP Morgan | Target lowered | Buy | $87 → $86 |
| Nov 3 | Oppenheimer | Target lowered | Buy | $97 → $94 |
| Nov 3 | RBC Capital | Target lowered | Hold | $62 → $60 |
| Nov 3 | Stifel | Maintained | Hold | $66 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is sitting right on its 200 day average, a level many traders watch. Momentum is strong (RSI 55). The nearest support is the 200 day average at $58.47, and the nearest resistance the 50 day average at $58.56.
| RSI (14) | 55.05 | Middle of its range | Neutral |
| MACD | -0.01 | Above its signal line | Bullish |
| Stochastic | 78.8 | Middle of its range | Neutral |
| ADX (14) | 16.9 | No clear trend | |
| Williams %R | -13.2 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 113.5 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +5.1% | Change over 10 sessions | Bullish |
| ATR (14) | $1.78 | Typical daily range, 3.0% of price |
| RSI (14) | 49.28 | Middle of its range | Neutral |
| MACD | -0.41 | Below its signal line | Bearish |
| Stochastic | 28.6 | Middle of its range | Neutral |
| ADX (14) | 21.0 | Weak trend | |
| Williams %R | -63.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -45.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −10.9% | Change over 10 sessions | Bearish |
| ATR (14) | $3.92 | Typical daily range, 6.7% of price |
What happened before
See how BMRN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BMRN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in BMRN in the last 90 days.
Dark Pool
30DBMRN Institutional Ownership
Full report →- ●282 buying vs 256 selling
- ▼Held by funds -6.6 pts
- ●Funds holding +3
- ●Superinvestors: 3 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 582 | 579 | +0.5% |
| In funds' top 10 | 17 | 14 | +21.4% |
| Held by funds | 100.0% | 106.6% | −6.6 pts |
| New / increased | 81 / 201 | 83 / 205 | −2.1% |
| Reduced / sold out | 184 / 72 | 196 / 82 | −7.9% |
| Put/call ratio | 0.44 | 0.35 | +23.9% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BMRN is in one of them and how their past BMRN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BMRN in an article yet. Here's the latest on the wider market.
BMRN Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Dan GoldmanD · NY | Sell | $1K – $15K | Mar 6, 2023 | Apr 17, 2023 | 42 d |
| Ro KhannaD · CA | Sell | $1K – $15K | Mar 14, 2023 | Apr 7, 2023 | 24 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Dec 6, 2022 | Jan 3, 2023 | 28 d |
| Ro KhannaD · CA | Sell | $1K – $15K | May 10, 2022 | Jun 10, 2022 | 31 d |
| Josh GottheimerD · NJ | Sell | $1K – $15K | Oct 18, 2021 | Nov 15, 2021 | 28 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Biomarin Pharmaceutical
BioMarin Pharmaceutical develops and sells medicines for people with rare genetic diseases. Its products include VOXZOGO, a treatment for achondroplasia, the most common form of short stature caused by a genetic condition, and several enzyme therapies for conditions such as mucopolysaccharidosis and phenylketonuria. The company is based in California, and its customers are patients and the specialists who prescribe its treatments.
- Headquarters
- Novato, CA
- Founded
- 1997
- Website
- biomarin.com ↗










